Health
Lunit Showcases AI Pathology Advances in Cancer Research from Rare to Common Tumors at AACR 2025
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30 in Chicago, Illinois. The presentations introduce Lunit's latest research in AI-based histopathology, featuring studies powered by the Lunit SCOPE® suite across a range of cancers—from rare salivary gland tumors to common types like lung canc
About this update from Lunit Inc.
[{"type":"text","content":"SEOUL, South Korea, April 22, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30 in Chicago, Illinois. The presentations introduce Lunit's latest research in AI-based histopathology, featuring studies powered by the Lunit SCOPE® suite across a range of cancers—from rare salivary gland tumors to common types like lung cancer.","length":558,"tagName":"p"},{"type":"image","alt":"Lunit presents seven studies—including joint research with global pharma leaders—at AACR 2025 Annual Meeting, showcasing how Lunit SCOPE® enables novel biomarker discovery across a range of tumors.","displaySize":"","headline":null,"caption":"Lunit presents seven studies—including joint research with global pharma leaders—at AACR 2025 Annual Meeting, showcasing how Lunit SCOPE® enables novel biomarker discovery across a range of tumors.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":222,"url":"https://media.zenfs.com/en/prnewswire.com/1012d4400548dd27955361e999791ead"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bkzh.2ovqlmv9kldFhKrrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1012d4400548dd27955361e999791ead","width":400,"height":222}},"href":"https://mma.prnewswire.com/media/2669718/Lunit_presents_studies_including_joint_research_global_pharma_leaders_at_AACR_2025.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The poster lineup includes two collaborative studies with global pharma leaders, including AstraZeneca. One study—conducted in partnership with AstraZeneca—presents the development and validation of an AI model that predicts EGFR mutations from H&E slides, enabling faster, more accessible mutation testing for NSCLC patients. Another, co-authored with a major global biotech company, applies Lunit SCOPE IO® to phase II and III clinical trial data to predict benefit from atezolizumab, revealing that AI-based histologic profiling can help stratify patients based on likely immunotherapy response.","length":602,"tagName":"p"},{"type":"text","content":"Among the seven studies to be pre...